Depemokimab Asthma Imaging and Bronchoscopy Sub-Study

To join this study, you would need to be an adult, aged 18 or older. You must have had a diagnosis of asthma for at least two years and your asthma needs to be well-documented by a doctor, following recognised guidelines in the UK, such as those from NICE or GINA. A key requirement is that you have a specific type of asthma where your blood tests show high levels of certain cells called eosinophils (meaning your count is 300 or more). Also, another breathing test (FeNO) needs to show a reading of 25 or higher, which indicates a particular kind of inflammation in your airways.

Your asthma should also be considered 'uncontrolled', even though you're already taking medium to high doses of inhaled steroids (ICS) and at least one other asthma controller medicine. This is usually checked using a questionnaire called ACQ-5, where your score would need to be above 1.5. Additionally, your doctor needs to confirm that you’ve had at least two severe asthma flare-ups in the last year that needed treatment with steroid tablets, injections, or drips. Your lung function, measured by a test called FEV1, would also need to be less than 80% of what is expected for someone your age and height.

While men have no specific extra requirements, women who might become pregnant would need to be using effective contraception throughout the study. Women who are pregnant or breastfeeding cannot take part. The research team will carefully check all these requirements to make sure the study is right for you and that you meet all the necessary criteria.

The detailed information about what taking part involves is not provided in your summary. We would expect information on the number of clinic visits, how often they occur, the types of tests and procedures that would be carried out (e.g., blood tests, lung function tests, bronchoscopies, imaging scans), how the study medication is given (e.g., injection, tablets), how long you would be taking the treatment, and any follow-up appointments after the treatment ends. The total duration of your participation, from your first screening appointment to your final follow-up, would also be provided.